This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Clinical Trial Assessing Safety of MF101 for Hot Flushes

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2011 by Bionovo.
Recruitment status was:  Active, not recruiting
Information provided by:
Bionovo Identifier:
First received: February 16, 2011
Last updated: June 1, 2011
Last verified: June 2011
This Phase 1, open label, randomized clinical trial will enroll 40 generally healthy, postmenopausal women aged 40-65 years old. Women will be randomized to one of two oral doses of MF101 for 4 weeks. Participants will be recruited at 3 clinical sites in the United States.

Condition Intervention Phase
Hot Flashes Drug: MF101 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Open Label, Randomized Clinical Trial Assessing Safety of MF101 for Hot Flushes and Menopausal Symptoms in Postmenopausal Women

Further study details as provided by Bionovo:

Primary Outcome Measures:
  • Evaluate the safety of MF101, 10 g/day and 15 g/day [ Time Frame: Randomization to 4 weeks ]
    New or worsening abnormalities on breast, physical and general exams, laboratory measures, transvaginal ultrasound, abnormal uterine bleeding, adverse events and serious adverse events.

Secondary Outcome Measures:
  • Compare the safety of MF101 10g/day and 15 g/day [ Time Frame: Randomization to 4 Weeks ]
    To compare the safety of the 2 doses of MF101

Estimated Enrollment: 40
Study Start Date: March 2011
Estimated Study Completion Date: June 2011
Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MF101 10 grams/day Drug: MF101
MF101 10 g/day MF101 15 g/day
Other Name: Menerba
Experimental: MF101 15 grams/day Drug: MF101
MF101 10 g/day MF101 15 g/day
Other Name: Menerba

Detailed Description:
MF101 is an oral, non-hormonal, botanical agent being investigated for the treatment of menopausal hot flashes.

Ages Eligible for Study:   40 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria (partial list):

  • Postmenopausal women aged 40-65 years.
  • Provide informed consent.
  • Currently receive medical care from a health care provider. Other inclusions apply.

Exclusion Criteria (partial list):

  • History of malignancy other than non-melanoma skin cancer or cervical cancer that was diagnosed and fully treated less than 5 years before screening.
  • Unexplained uterine bleeding within 6 months prior to Screening.
  • History of deep vein thrombosis or pulmonary embolism.
  • Active liver disease or a history of impaired.
  • Active gallbladder disease. Other exclusions apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01300078

United States, California
Alta Bates, Jordan Research and Education Institute (REDI)
Berkeley, California, United States, 94705
Clinical Trials Research
Lincoln, California, United States, 95648
Northern California Research
Sacramento, California, United States, 95821
Medical Center for Clinical Research
San Diego, California, United States, 92108
Sponsors and Collaborators
Principal Investigator: Wulf Utian, PhD, DSc(Med), FRCOG, FACOG
  More Information

Responsible Party: Mary Tagliaferri, MD, LAc/President and CMO, Bionovo Identifier: NCT01300078     History of Changes
Other Study ID Numbers: MF101-008
Study First Received: February 16, 2011
Last Updated: June 1, 2011

Keywords provided by Bionovo:
Hot Flashes
Hot Flushes
Vasomotor Symptoms
Menopausal Symptoms

Additional relevant MeSH terms:
Hot Flashes
Signs and Symptoms processed this record on September 21, 2017